Kocsis J H, Mason B J, Frances A J, Sweeney J, Mann J J, Marin D
Department of Psychiatry, New York Hospital-Cornell Medical Center, NY 10021.
J Affect Disord. 1989 Nov-Dec;17(3):255-60. doi: 10.1016/0165-0327(89)90008-6.
We had previously reported that imipramine was superior to placebo for the treatment of chronic depression. As a part of that study, we subsequently investigated clinical and demographic variables which might be associated with favorable or poor outcome for treatment with imipramine or placebo. Results are reported herein. Eight-six patients were entered and 53 completed an 8-week protocol. Outcome was assessed based on a 6-week, double-blind treatment phase, which followed a 2-week, single-blind placebo phase. Outcome was not found to significantly relate to demographic variables, severity or course of depression, diagnostic subtype, symptom profile, or DST results. Some modest associations were found between 'neurotic' personality traits and poor outcome. Results are discussed and compared with prior studies of prediction of tricyclic antidepressant response in both acute and chronic depressions.
我们之前曾报道，丙咪嗪在治疗慢性抑郁症方面优于安慰剂。作为该研究的一部分，我们随后调查了可能与丙咪嗪或安慰剂治疗的良好或不良结果相关的临床和人口统计学变量。本文报告了研究结果。86名患者入组，53名完成了为期8周的方案。结局基于为期6周的双盲治疗阶段进行评估，该阶段之前是为期2周的单盲安慰剂阶段。未发现结局与人口统计学变量、抑郁症的严重程度或病程、诊断亚型、症状谱或地塞米松抑制试验结果有显著关联。发现“神经质”人格特质与不良结果之间存在一些适度的关联。本文对研究结果进行了讨论，并与先前关于急性和慢性抑郁症中三环类抗抑郁药反应预测的研究进行了比较。
